Extended-interval ("once-daily") aminoglycoside dosing nomogram — concentration-dependent killing, post-antibiotic effect, and renal-function-based interval selection
Aminoglycosides (gentamicin, tobramycin, amikacin) belong to a class of antibiotics whose bactericidal activity is driven primarily by how far the peak serum concentration rises above the minimum inhibitory concentration (MIC) of the target organism — not by how long the concentration is sustained above MIC, as with beta-lactams. This single pharmacodynamic fact is the entire rationale for extended-interval, once-daily dosing.
Antibiotics fall broadly into two pharmacodynamic categories:
Concentration-dependent agents (aminoglycosides, fluoroquinolones): • Rate and extent of bacterial kill increases as the peak concentration rises further above MIC • The relevant index is Cmax/MIC (or AUC/MIC over 24h) • A single large dose that produces a high peak kills more efficiently than the same total amount given as several smaller doses • Clinical target for aminoglycosides: Cmax/MIC of approximately 8–10:1 is associated with the highest probability of bacteriologic cure and the lowest risk of emergence of resistant subpopulations
Time-dependent agents (beta-lactams, vancomycin): • Kill rate plateaus once concentration exceeds MIC by a modest margin • What matters is the percentage of the dosing interval that concentration remains above MIC (%T>MIC) • Continuous or frequent dosing — not a high peak — maximizes effect
Because aminoglycosides are concentration-dependent, splitting a fixed total daily dose into multiple smaller doses (traditional dosing, e.g., q8h) blunts the peak and paradoxically reduces bactericidal efficiency relative to giving the entire amount as a single larger dose once daily.
Consider a fixed 24-hour total dose delivered two different ways:
Traditional multiple-daily dosing (e.g., 2 mg/kg q8h × 3 doses): • Each individual peak is modest • Cmax/MIC ratio for any single dose may fall short of the 8–10:1 target against less susceptible organisms • Troughs between doses are relatively shallow, so drug never fully clears from renal tissue
Extended-interval dosing (e.g., 6 mg/kg once daily): • The entire daily dose is concentrated into a single large peak • Cmax/MIC ratio is maximized, improving the speed and completeness of bacterial kill • Because clearance is renal and roughly first-order, the same total AUC is delivered over 24h, but reshaped into one tall peak followed by a long trough
This reshaping — same total exposure, redistributed into a single higher peak — is the pharmacokinetic maneuver underlying every extended-interval nomogram.
Simulated model: a single 7 mg/kg peak achieves a substantially higher Cmax/MIC ratio than the same 7 mg/kg total split across three 2.3 mg/kg doses — translating into faster, more complete bacterial kill in vitro and in animal infection models.
Aminoglycosides also exhibit a pronounced post-antibiotic effect (PAE): bacterial regrowth remains suppressed for a period of time even after the serum concentration has fallen below the MIC. This residual suppression is what makes it pharmacodynamically safe to widen the dosing interval well beyond what the elimination half-life alone would suggest.
Aminoglycosides bind irreversibly to the bacterial 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional or truncated proteins. Even after free drug has diffused out of the bacterial cell and serum levels drop below MIC:
• Ribosomes and associated translation machinery remain functionally impaired • Bacteria require time to resynthesize functional ribosomal components and resume normal protein synthesis • During this recovery window, the bacterial population does not resume exponential growth, even though no drug is measurably present
This differs fundamentally from a purely pharmacokinetic "coverage gap" — it is an active, drug-induced suppression of bacterial recovery that persists after the pharmacokinetic curve has moved on.
The duration of the post-antibiotic effect for aminoglycosides is not fixed — it lengthens as the peak concentration achieved during exposure increases:
• Higher Cmax/MIC exposures produce longer PAE, typically in the range of 2–8 hours for susceptible gram-negative organisms • This creates a favorable feedback loop for extended-interval dosing: consolidating the daily dose into one large peak (Stage 1) simultaneously maximizes bactericidal kill AND prolongs the PAE that follows • The combination of concentration-dependent killing plus a peak-dependent PAE means the interval between doses can be extended well beyond the point where serum concentration crosses below MIC, without any loss of bacteriologic control
This is the second pillar (alongside concentration-dependent killing) that justifies once-daily rather than divided dosing.
Because both bactericidal efficiency and PAE duration increase with a higher peak, extended-interval dosing is not a compromise for convenience — it is pharmacodynamically favorable compared with traditional divided dosing, for organisms with typical susceptibility.
Extended-interval regimens consolidate the total daily dose — typically 4 to 7 mg/kg/day for gentamicin or tobramycin equivalents — into one infusion given every 24 hours in patients with normal renal function, and every 36 or 48 hours as estimated creatinine clearance declines. The dose itself is calculated from an appropriate weight estimate and the chosen mg/kg/day target.
The illustrative calculation performed by this simulator is:
Once-daily dose (mg) = target dose (mg/kg/day) × weight (kg)
For a 70 kg reference patient with a target of 5.5 mg/kg/day: 5.5 × 70 = 385 mg, given as a single infusion once daily (subject to interval extension for renal impairment)
In real clinical practice, the weight used is not always actual body weight: • Actual body weight (ABW): used for patients at or near ideal body weight • Ideal body weight (IBW): used as a floor for underweight patients • Adjusted body weight: used for obese patients, since aminoglycosides distribute poorly into excess adipose tissue — dosing on actual weight in obesity risks supratherapeutic peaks
The mg/kg/day target itself varies by drug and indication: gentamicin/tobramycin extended-interval regimens commonly range 4–7 mg/kg/day, while amikacin (dosed at roughly 3x the mg/kg of gentamicin) uses a different scale entirely.
Once the total daily dose is calculated, extended-interval protocols administer the entire amount as one intravenous infusion — commonly over 30–60 minutes — rather than dividing it into two or three smaller infusions across the day.
Practical dosing considerations: • Nursing and administration burden is reduced: one infusion per day (or every 36–48h) instead of three • Peak levels are not typically monitored dose-by-dose in extended-interval protocols the way they are for traditional dosing; instead, a single post-dose level is used to select the interval via nomogram (Stage 4) • The first dose is generally given at the calculated mg/kg amount regardless of renal function; it is the interval — not the dose per administration — that lengthens as renal clearance falls
This decoupling of "how much drug per dose" from "how often" is what allows the same weight-based dose calculation to apply across a wide range of renal function, with the nomogram doing the work of individualizing frequency.
After the first extended-interval dose is given, a single serum concentration drawn at a defined time point post-infusion is plotted on a nomogram — a graph of concentration against time since the start of infusion, divided into bands corresponding to q24h, q36h, and q48h dosing. The band the point falls into becomes the recommended interval for that patient.
Extended-interval nomograms (e.g., the Hartford nomogram for gentamicin/tobramycin) are built from population pharmacokinetic data correlating a single post-dose concentration, drawn at a specified time window after the start of infusion, with the elimination rate expected for a given renal function.
Reading the nomogram: • X-axis: hours elapsed since the start of the infusion at the time the level was drawn (commonly 6–14 hours post-dose) • Y-axis: measured serum concentration (mg/L) • The plotted point falls into one of several diagonal bands, each corresponding to a recommended interval: q24h, q36h, or q48h • A point falling above the highest band suggests drug is clearing more slowly than expected (reduced renal function) and warrants an even longer interval, individualized dosing, or a switch away from extended-interval dosing altogether
The nomogram approach avoids requiring multiple levels (peak and trough) for every patient — a single well-timed level is usually sufficient to confirm or adjust the interval predicted from estimated creatinine clearance.
Because aminoglycosides are cleared almost entirely by glomerular filtration, estimated creatinine clearance (CrCl) is the dominant variable determining how long the interval should be:
• CrCl ≥ 60 mL/min: elimination is rapid enough that a full 24-hour interval reliably produces an adequate trough — q24h dosing • CrCl 40–59 mL/min: elimination is slower; extending to q36h preserves an adequate trough period • CrCl 20–39 mL/min: further extension to q48h is generally needed • CrCl < 20 mL/min: extended-interval nomograms were not developed for this population — dosing typically requires individualized pharmacokinetic calculation or a switch to traditional dosing with level-based adjustment
The nomogram level, drawn after the first dose, serves as a confirmatory check on the interval predicted from the estimated CrCl — accounting for the fact that estimated renal function can diverge from a patient's actual clearance.
The nomogram and the CrCl-based interval estimate are meant to be used together: CrCl guides the starting interval, and the post-dose level confirms or corrects it once real pharmacokinetic behavior is observed.
Aminoglycoside nephrotoxicity results from drug accumulation in renal proximal tubular cells via saturable uptake transporters. Extended-interval dosing is associated with a lower risk of nephrotoxicity than traditional multiple-daily dosing because it guarantees a sustained drug-free trough period during which those transporters are no longer saturated and tubular cells can clear accumulated drug and recover.
Aminoglycosides accumulate in the renal cortex via megalin-mediated endocytosis at the proximal tubular brush border. Critically, this uptake mechanism is saturable, not linearly proportional to serum concentration:
• At high peak concentrations, the uptake transporters become saturated — additional drug above a certain concentration is not taken up proportionally faster • At low (trough) concentrations sustained over a period of time, transporters remain engaged and continue accumulating drug, even though the serum level itself is low • This means a schedule with a brief but shallow trough between doses (traditional multiple-daily dosing) can result in more cumulative tubular drug uptake than a schedule with one large peak followed by a long true trough (extended-interval dosing)
In other words, it is prolonged low-level exposure — not the height of the peak — that drives cumulative tubular accumulation and toxicity risk.
Extended-interval dosing is specifically designed to produce a genuine drug-free (or near drug-free) trough period between doses:
• During this window, serum and peritubular drug concentrations fall low enough that megalin-mediated uptake slows substantially • Renal proximal tubular cells are given time to process, exocytose, or otherwise clear drug that accumulated during the peak, rather than facing continuous re-loading from a shallow trough • This recovery window is the direct mechanistic parallel to the drug-free interval needed at the tissue level, distinct from the serum pharmacokinetics discussed in Stage 4
Because traditional multiple-daily dosing keeps the trough relatively elevated across all doses, tubular cells rarely get this true recovery window — contributing to the comparatively higher nephrotoxicity signal seen with traditional regimens in clinical studies.
Multiple randomized trials and meta-analyses comparing extended-interval to traditional multiple-daily aminoglycoside dosing have found comparable or improved clinical efficacy with a lower or equivalent incidence of nephrotoxicity — reinforcing that the drug-free trough is protective rather than merely a convenience.
When estimated creatinine clearance is low, the trough window achieved even by an extended interval may not be fully drug-free by the time the next dose is due, since elimination itself is slower:
• This is precisely why the nomogram (Stage 4) recommends progressively longer intervals — q36h, q48h, or individualized dosing — as CrCl declines, in order to preserve an adequate trough despite slower clearance • In patients with lower or fluctuating renal function, closer monitoring of renal function (serial creatinine) and, where appropriate, serum aminoglycoside levels is prudent to confirm the trough is being achieved as intended • The combination of weight-based dose calculation (Stage 3), nomogram-confirmed interval (Stage 4), and attention to trough adequacy (Stage 5) together form the safety framework of extended-interval dosing